Smoking Cessation Drug Tied to Increased Cardiovascular Risk

This article originally appeared here.
Share this content:
Smoking Cessation Drug Tied to Increased Cardiovascular Risk
Smoking Cessation Drug Tied to Increased Cardiovascular Risk

WEDNESDAY, Dec. 27, 2017 (HealthDay News) -- Individuals taking varenicline for smoking cessation appear to be at increased risk of cardiovascular but not neuropsychiatric events, according to a study published online Dec. 20 in the American Journal of Respiratory and Critical Care Medicine.

Andrea S. Gershon, M.D., from the Sunnybrook Health Sciences Centre in Toronto, and colleagues assessed the risks of cardiovascular and neuropsychiatric events in the first 12 weeks after varenicline receipt among 56,851 new users (from Sept. 1, 2011, to Feb. 15, 2014) in a real-world setting.

The researchers found that 6,317 cardiovascular and 10,041 neuropsychiatric hospitalizations and emergency department visits occurred from one year before to one year after receipt of the drug. In the 12 weeks after varenicline receipt, the incidence of cardiovascular events was 34 percent higher compared with the remaining observation period. Even in those without any history of previous cardiovascular disease, the findings remained consistent in sensitivity analyses. For neuropsychiatric events, the relative incidence was marginally significant in primary analyses (1.06; 95 percent confidence interval, 1.0 to 1.13) but not in all sensitivity analyses.

"Varenicline appears to be associated with an increased risk of cardiovascular but not neuropsychiatric events," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Vaccine Hesitancy a Major Global Health Threat

WHO: Vaccine Hesitancy a Major Global Health Threat

Percentage of U.S. children 19 to 35 months who have not been vaccinated has quadrupled since 2001

FDA Down to 5 Weeks of Funding to Review New Drug Applications

FDA Down to 5 Weeks of Funding to ...

Agency cannot accept new fees or applications until the shutdown is over

FDA Approves First Generic Version of Epilepsy Drug Sabril

FDA Approves First Generic Version of Epilepsy Drug ...

Generic equivalents held to same vigorous manufacturing standards as brand-name drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »